PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RXRX vs. INTU
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RXRX and INTU is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

RXRX vs. INTU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Intuit Inc. (INTU). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-14.19%
-4.78%
RXRX
INTU

Key characteristics

Sharpe Ratio

RXRX:

-0.42

INTU:

0.05

Sortino Ratio

RXRX:

-0.15

INTU:

0.25

Omega Ratio

RXRX:

0.98

INTU:

1.03

Calmar Ratio

RXRX:

-0.42

INTU:

0.08

Martin Ratio

RXRX:

-0.77

INTU:

0.19

Ulcer Index

RXRX:

47.47%

INTU:

6.98%

Daily Std Dev

RXRX:

85.72%

INTU:

28.12%

Max Drawdown

RXRX:

-88.97%

INTU:

-75.29%

Current Drawdown

RXRX:

-84.20%

INTU:

-14.32%

Fundamentals

Market Cap

RXRX:

$2.51B

INTU:

$169.99B

EPS

RXRX:

-$1.57

INTU:

$10.21

Total Revenue (TTM)

RXRX:

$54.29M

INTU:

$16.59B

Gross Profit (TTM)

RXRX:

$14.55M

INTU:

$12.99B

EBITDA (TTM)

RXRX:

-$262.33M

INTU:

$4.31B

Returns By Period

In the year-to-date period, RXRX achieves a -3.40% return, which is significantly higher than INTU's -3.72% return.


RXRX

YTD

-3.40%

1M

5.07%

6M

-14.19%

1Y

-33.97%

5Y*

N/A

10Y*

N/A

INTU

YTD

-3.72%

1M

-6.87%

6M

-4.78%

1Y

-0.58%

5Y*

17.18%

10Y*

22.37%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RXRX vs. INTU — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX
The Risk-Adjusted Performance Rank of RXRX is 2626
Overall Rank
The Sharpe Ratio Rank of RXRX is 2424
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2828
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2828
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 2121
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 3030
Martin Ratio Rank

INTU
The Risk-Adjusted Performance Rank of INTU is 4545
Overall Rank
The Sharpe Ratio Rank of INTU is 4848
Sharpe Ratio Rank
The Sortino Ratio Rank of INTU is 4040
Sortino Ratio Rank
The Omega Ratio Rank of INTU is 3939
Omega Ratio Rank
The Calmar Ratio Rank of INTU is 4949
Calmar Ratio Rank
The Martin Ratio Rank of INTU is 4848
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RXRX vs. INTU - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Intuit Inc. (INTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RXRX, currently valued at -0.42, compared to the broader market-2.000.002.004.00-0.420.05
The chart of Sortino ratio for RXRX, currently valued at -0.15, compared to the broader market-4.00-2.000.002.004.00-0.150.25
The chart of Omega ratio for RXRX, currently valued at 0.98, compared to the broader market0.501.001.502.000.981.03
The chart of Calmar ratio for RXRX, currently valued at -0.42, compared to the broader market0.002.004.006.00-0.420.08
The chart of Martin ratio for RXRX, currently valued at -0.77, compared to the broader market-10.000.0010.0020.0030.00-0.770.19
RXRX
INTU

The current RXRX Sharpe Ratio is -0.42, which is lower than the INTU Sharpe Ratio of 0.05. The chart below compares the historical Sharpe Ratios of RXRX and INTU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
-0.42
0.05
RXRX
INTU

Dividends

RXRX vs. INTU - Dividend Comparison

RXRX has not paid dividends to shareholders, while INTU's dividend yield for the trailing twelve months is around 0.64%.


TTM20242023202220212020201920182017201620152014
RXRX
Recursion Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
INTU
Intuit Inc.
0.64%0.60%0.52%0.72%0.38%0.57%0.74%0.83%0.89%1.08%1.09%0.89%

Drawdowns

RXRX vs. INTU - Drawdown Comparison

The maximum RXRX drawdown since its inception was -88.97%, which is greater than INTU's maximum drawdown of -75.29%. Use the drawdown chart below to compare losses from any high point for RXRX and INTU. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-84.20%
-14.32%
RXRX
INTU

Volatility

RXRX vs. INTU - Volatility Comparison

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 28.74% compared to Intuit Inc. (INTU) at 6.74%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than INTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
28.74%
6.74%
RXRX
INTU

Financials

RXRX vs. INTU - Financials Comparison

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Intuit Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab